Newsletter | August 10, 2011

8.10.11 -- Clinical Trial Diversity Blog Prompts Phone Call

Clinical Leader
Clinical Trial Diversity Blog Prompts Phone Call
By Rob Wright, Chief Editor, Life Science Leader magazine

Rob Wright, Chief Editor, <u>Life Science Leader</u> magazine In July, I wrote a blog entitled, "Controversy: Alive and Well at Bio International." The second subhead reads, "Clinical Trial Diversity Still Sits at the Back of the Bus." Apparently this got some folks' attention. James Gillespie, Ph.D., J.D. is the president of the Center for Healthcare Innovation. He decided to give me a call about my blog. I half expected the call to be a criticism for my choice of words, but to my delight, it was just the opposite.
Read more.

Featured Articles

Industry Survey: Clinical Study Budgeting Practices And Metrics
The results of the survey clearly show that the life sciences industry continues to experience difficulty accurately predicting spending for its most costly area: clinical development. Read more.

Eight Steps To More Productive Observational Studies
The automobile industry is in a precarious state. With factories designed to churn out light trucks, SUVs, and other gas-guzzlers, the industry has been ill-prepared for the shift toward energy-efficient vehicles. Is this an allegory for the pharmaceutical industry? Perhaps. Read more.

Sponsor, Site, And CRO Views On BestPractices In Clinical Trial Conduct
Estimates vary, but up to 30% of investigators fail to recruit a single patient, and many more do not meet their contractual target. These woeful figures are not new. However, given that poor enrollment is a longstanding problem, have we, as an industry, simply come to accept this as status quo? Read more.

Product Of The Week

Oncology Clinical Trials And Studies
Oncology is currently ICON's fastest-growing therapeutic area and a testament to our success in conducting oncology clinical trials. To date, ICON has conducted over 870 oncology studies, assessing over 143,000 patients at nearly 24,000 sites worldwide. Read more.

Top News